DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)

South Korea · Delayed Price · Currency is KRW

24,450

+550 (2.30%)

Oct 23, 2026, 3:30 PM KST

Market Cap	1.10T +33.7%
Revenue (ttm)	979.60B +12.7%
Net Income	76.41B +26.9%
EPS	1,697.55 +26.3%
Shares Out	45.11M
PE Ratio	14.40
Forward PE	12.41
Dividend	200.00 (0.82%)
Ex-Dividend Date	Dec 29, 2025

Volume	449,760
Open	23,600
Previous Close	23,900
Day's Range	23,450 - 24,650
52-Week Range	16,260 - 31,250
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd., established in Seoul, South Korea in 1968, operates as a pharmaceutical company with a broad presence both domestically and globally. Formerly known as UEC & Co., Ltd. until its rebranding in March 1982, the firm manufactures and distributes a diverse array of healthcare products. Its offerings include essential active pharmaceutical ingredients like propofol, streptokinase, and teicoplanin. The company also produces a wide range of finished drug forms such as disposable syringes, tablets, capsules, and topica... [Read more]

Industry Medical - Pharmaceuticals

Sector Healthcare

Founded 1968

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 086450

Full Company Profile

Financial Performance

In 2025, DongKook Pharmaceutical's revenue was 926.88 billion, an increase of 14.12% compared to the previous year's 812.17 billion. Earnings were 66.02 billion, an increase of 8.64%.

Financial Statements